PDCD1 and neoplasm: Analysis of the tumors revealed that the combined anti-PD-1/IGF1R treatment led to a significant decrease in the mean tumor mass compared to mice treated with either the anti-PD-1 or the IGF1R inhibitor (34% and 40% decreases, respectively; Figure 4B).